Andrew S Levey

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7894923/publications.pdf

Version: 2024-02-01

490 papers	135,867 citations	403 137 h-index	103 360 g-index
497 all docs	497 docs citations	497 times ranked	74699 citing authors

#	Article	IF	Citations
1	Removing race from the CKD-EPI equation and its impact on prognosis in a predominantly White European population. Nephrology Dialysis Transplantation, 2023, 38, 119-128.	0.4	21
2	Defining AKD: The Spectrum of AKI, AKD, and CKD. Nephron, 2022, 146, 302-305.	0.9	47
3	A metabolomics approach identified toxins associated with uremic symptoms in advanced chronic kidney disease. Kidney International, 2022, 101, 369-378.	2.6	3
4	National Kidney Foundation Laboratory Engagement Working Group Recommendations for Implementing the CKD-EPI 2021 Race-Free Equations for Estimated Glomerular Filtration Rate: Practical Guidance for Clinical Laboratories. Clinical Chemistry, 2022, 68, 511-520.	1.5	70
5	A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors. Kidney International, 2022, 101, 607-614.	2.6	22
6	Î²2-Microglobulin and Î²-Trace Protein in Patients Undergoing Bariatric Surgery: Non-GFR Determinants and Panel-estimated GFR Performance. Kidney Medicine, 2022, 4, 100401.	1.0	0
7	Serum metabolomic signatures of plant-based diets and incident chronic kidney disease. American Journal of Clinical Nutrition, 2022, 116, 151-164.	2.2	11
8	Performance of Serum Î²2-Microglobulinâ€“ and Î²-Trace Proteinâ€“Based Panel Markers and 2021 Creatinine- and Cystatin-Based GFR Estimating Equations in Pakistan. Kidney Medicine, 2022, 4, 100444.	1.0	5
9	The authors reply:. Kidney International, 2022, 101, 1088-1089.	2.6	0
10	FC078: Impact of Removing Race from the CKD-EPI Equation: Analysis of 1.6 Million Swedish Adults. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	5
11	FC078: Impact of Removing Race from the CKD-EPI Equation: Analysis of 1.6 Million Swedish Adults. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
12	Uses of GFR and Albuminuria Level in Acute and Chronic Kidney Disease. New England Journal of Medicine, 2022, 386, 2120-2128.	13.9	58
13	Performance of the 2021 CKD-EPI equations without a race coefficient in a multi-racial population of adults with solid tumors: A prospective cross-sectional study.. Journal of Clinical Oncology, 2022, 40, 12064-12064.	0.8	2
14	Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Peritoneal Dialysis International, 2021, 41, 5-14.	1.1	4
15	Nomenclature for kidney function and disease: Executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. American Journal of Transplantation, 2021, 21, 901-902.	2.6	4
16	Cystatin C and Muscle Mass in Patients With Heart Failure. Journal of Cardiac Failure, 2021, 27, 48-56.	0.7	10
17	Long-Term Longitudinal Stability of Kidney Filtration Marker Measurements: Implications for Epidemiological Studies and Clinical Care. Clinical Chemistry, 2021, 67, 425-433.	1.5	12
18	Improving Glomerular Filtration Rate Estimationâ€”Across the Age and Diversity Spectrum. Annals of Internal Medicine, 2021, 174, 265-267.	2.0	10

#	Article	IF	Citations
19	Tubular Secretion of Creatinine and Risk of Kidney Failure: The Modification of Diet in Renal Disease (MDRD) Study. American Journal of Kidney Diseases, 2021, 77, 992-994.	2.1	5
20	The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2021, 99, 34-47.	2.6	195
21	Estimating Kidney Failure Risk Using Electronic Medical Records. Kidney360, 2021, 2, 415-424.	0.9	9
22	Evaluation of Glomerular Filtration Rate, Albuminuria and Hematuria in Living Donor Candidates. , 2021, , 59-91.		0
23	Promoting Equity in Eligibility for Registration on the Kidney Transplantation Waiting List: Looking beyond eGFRcr. Journal of the American Society of Nephrology: JASN, 2021, 32, 523-525.	3.0	4
24	In Search of a Better Equation â€" Performance and Equity in Estimates of Kidney Function. New England Journal of Medicine, 2021, 384, 396-399.	13.9	92
25	New GFR-estimating equations for children and young adults in North America and Europe. Kidney International, 2021, 99, 808-811.	2.6	0
26	Performance and Determinants of Serum Creatinine and Cystatin Câ€“Based GFR Estimating Equations in South Asians. Kidney International Reports, 2021, 6, 962-975.	0.4	14
27	A New Panel-Estimated GFR, Including Î²2-Microglobulin and Î²-Trace Protein and Not Including Race, Developed in a Diverse Population. American Journal of Kidney Diseases, 2021, 77, 673-683.e1.	2.1	47
28	In Reply to â€œMultiple-Biomarker Panel Estimated GFR Is Not Optimal or Cost-Effectiveâ€•and â€œComparing Multiple-Biomarker Panels for Estimating GFR With Estimating Equations Without a Coefficient Distinguishing Black Individuals From Persons of Other Groupsâ€• American Journal of Kidney Diseases, 2021, 77, 824.	2.1	1
29	Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations. Diabetes Care, 2021, 44, 2000-2009.	4.3	50
30	Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis. American Journal of Kidney Diseases, 2021, 78, 340-349.e1.	2.1	28
31	New Creatinine- and Cystatin Câ€“Based Equations to Estimate GFR without Race. New England Journal of Medicine, 2021, 385, 1737-1749.	13.9	1,236
32	Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International, 2021, 100, 516-526.	2.6	156
33	eGFR and chemotherapy: will removing race create disparities?. Lancet Oncology, The, 2021, 22, 1208-1209.	5.1	3
34	Standardised Outcomes in Nephrology â€“ Chronic Kidney Disease (SONG-CKD): a protocol for establishing a core outcome set for adults with chronic kidney disease who do not require kidney replacement therapy. Trials, 2021, 22, 612.	0.7	12
35	AJKD at 40: The Boston Eraâ€"Years 25-35 (2007-2016). American Journal of Kidney Diseases, 2021, 78, 475-476.	2.1	0
36	CKD and Risk of Incident Hospitalization With Clostridioides Difficile Infection: Findings From the Atherosclerosis Risk in Communities (ARIC) Study. American Journal of Kidney Diseases, 2021, , .	2.1	0

#	Article	IF	Citations
37	Measured and estimated glomerular filtration rate: current status and future directions. Nature Reviews Nephrology, 2020, 16, 51-64.	4.1	166
38	Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. American Journal of Kidney Diseases, 2020, 75, 84-104.	2.1	311
39	â€œShould the definition of CKD be changed to include age-adapted GFR criteria?â€• Kidney International, 2020, 97, 37-40.	2.6	28
40	Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Medicine, 2020, 2, 373-376.	1.0	3
41	Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes Consensus Conference. Transplantation, 2020, 104, 1986-1994.	0.5	4
42	Nomenclature for kidney function and disease: Executive summary and glossary from a Kidney Disease: Improving Global Outcomes consensus conference. Journal of Onco-Nephrology, 2020, 4, 71-80.	0.3	0
43	Nomenclature for kidney function and disease: Executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. Diabetes Research and Clinical Practice, 2020, 165, 108248.	1.1	12
44	Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. Renal Failure, 2020, 42, 560-566.	0.8	5
45	Nomenclature for Kidney Function and Disease: Executive Summary and Glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Diseases (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.2	18
46	Integrated Risk Assessment Versus Age-Specific GFR Thresholds for Living Donor Candidate Evaluation. Transplantation, 2020, 104, 2464-2466.	0.5	3
47	Nomenclature for kidney function and disease: Executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Nephrology, 2020, 25, 589-598.	0.7	3
48	Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. Journal of Nephrology, 2020, 33, 639-648.	0.9	5
49	Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Seminars in Nephrology, 2020, 40, 329-337.	0.6	1
50	Editorial: Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes consensus conference. Current Opinion in Nephrology and Hypertension, 2020, 29, 537-546.	1.0	1
51	Nomenclature for kidney function and disease: Executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Journal of Renal Care, 2020, 46, 136-136.	0.6	3
52	Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes consensus conference*. CKJ: Clinical Kidney Journal, 2020, 13, 485-493.	1.4	11
53	Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. Pediatric Nephrology, 2020, 35, 2191-2200.	0.9	4
54	Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global OutcomesÂconsensus conference*. Nephrology Dialysis Transplantation, 2020, 35, 1077-1084.	0.4	8

#	Article	IF	Citations
55	Estimating Glomerular Filtration Rate in African American Individualsâ€"Reply. JAMA Internal Medicine, 2020, 180, 1549.	2.6	0
56	Performance of Glomerular Filtration Rate Estimating Equations Before and After Bariatric Surgery. Kidney Medicine, 2020, 2, 699-706.e1.	1.0	21
57	Nomenclature for kidney function and diseaseâ€"executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. European Heart Journal, 2020, 41, 4592-4598.	1.0	44
58	Incorporating kidney disease measures into cardiovascular risk prediction: Development and validation in 9 million adults from 72 datasets. EClinicalMedicine, 2020, 27, 100552.	3.2	50
59	Kidney Disease, Race, and GFR Estimation. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1203-1212.	2.2	168
60	Bisphosphonate utilization across the spectrum of eGFR. Archives of Osteoporosis, 2020, 15, 69.	1.0	4
61	Nomenclature for kidney function and disease: executive summary from a KDIGO consensus conference. Nature Reviews Nephrology, 2020, 16, 427-428.	4.1	2
62	Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR. Kidney International Reports, 2020, 5, 734-737.	0.4	2
63	GFR in Healthy Aging: an Individual Participant Data Meta-Analysis of Iohexol Clearance in European Population-Based Cohorts. Journal of the American Society of Nephrology: JASN, 2020, 31, 1602-1615.	3.0	68
64	GFR after kidney donation: early recovery and subsequent decline. Kidney International, 2020, 98, 57-59.	2.6	2
65	Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International, 2020, 97, 1117-1129.	2.6	407
66	Patient and Caregiver Perspectives on Terms Used to Describe Kidney Health. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 937-948.	2.2	47
67	Nomenclature for Kidney Function and Disease: Executive Summary and Glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. American Journal of Nephrology, 2020, 51, 579-588.	1.4	1
68	Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International Reports, 2020, 5, 965-972.	0.4	7
69	GFR Estimation Using a Panel of Filtration Markers in Shanghai and Beijing. Kidney Medicine, 2020, 2, 172-180.	1.0	6
70	Estimating total small solute clearance in patients treated with continuous ambulatory peritoneal dialysis without urine and dialysate collection. Peritoneal Dialysis International, 2020, 40, 84-92.	1.1	2
71	Global, regional, and national burden of chronic kidney disease, 1990â€"2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 709-733.	6.3	2,858
72	Estimation of Glomerular Filtration Rate With vs Without Including Patient Race. JAMA Internal Medicine, 2020, 180, 793.	2.6	64

#	Article	IF	Citations
73	Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Transplant International, 2020, 33, 999-1009.	0.8	5
74	Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International, 2020, 98, 294-309.	2.6	254
75	Application of the 2017 KDIGO Guideline for the Evaluation and Care of Living Kidney Donors to Clinical Practice. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 896-905.	2.2	19
76	Comparability of Plasma Iohexol Clearance Across Population-Based Cohorts. American Journal of Kidney Diseases, 2020, 76, 54-62.	2.1	9
77	Patient and Caregiver Priorities for Outcomes in CKD: A Multinational Nominal Group Technique Study. American Journal of Kidney Diseases, 2020, 76, 679-689.	2.1	56
78	Performance of Indexed and Nonindexed Estimated GFR. American Journal of Kidney Diseases, 2020, 76, 446-449.	2.1	19
79	Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. American Journal of Kidney Diseases, 2020, 76, 157-160.	2.1	8
80	Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. , 2020, 30, e41-e50.		2
81	Chronic Kidney Disease and Kidney Cancer Surgery: New Perspectives. Journal of Urology, 2020, 203, 475-485.	0.2	25
82	Nomenclature for kidney function and disease: Executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Research and Clinical Practice, 2020, 39, 151-161.	0.9	8
83	Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial. American Journal of Kidney Diseases, 2019, 73, 51-61.	2.1	30
84	Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data. Journal of the American Society of Nephrology: JASN, 2019, 30, 1746-1755.	3.0	109
85	Knowing your GFRâ€"when is the number not (exactly) the number?. Kidney International, 2019, 96, 280-282.	2.6	2
86	Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation. Journal of the American Society of Nephrology: JASN, 2019, 30, 1756-1769.	3.0	71
87	Validation of a simple equation for glomerular filtration rate measurement based on plasma iohexol disappearance. CKJ: Clinical Kidney Journal, 2019, 13, 397-401.	1.4	3
88	Novel associations between blood metabolites and kidney function among Bogalusa Heart Study and Multi-Ethnic Study of Atherosclerosis participants. Metabolomics, 2019, 15, 149.	1.4	13
89	GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. Journal of the American Society of Nephrology: JASN, 2019, 30, 1735-1745.	3.0	163
90	Strengths and limitations of estimated and measured GFR. Nature Reviews Nephrology, 2019, 15, 784-784.	4.1	38

#	Article	IF	Citations
91	Kidney Transplantation in Lupus Nephritis: Can We Do Even Better?. Annals of Internal Medicine, 2019, 170, 266.	2.0	1
92	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 2019, 21, 1199-1208.	2.2	83
93	Blood Pressure, Chronic Kidney Disease Progression, and Kidney Allograft Failure in Kidney Transplant Recipients: A Secondary Analysis of the FAVORIT Trial. American Journal of Hypertension, 2019, 32, 816-823.	1.0	8
94	A Combination of Change in Albuminuria and GFR as a Surrogate End Point for Progression of CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 792-794.	2.2	4
95	Development and Validation of Residual Kidney Function Estimating Equations in Dialysis Patients. Kidney Medicine, 2019, 1, 104-114.	1.0	9
96	Improving glomerular filtration rate estimation. Kidney International, 2019, 95, 1017-1019.	2.6	5
97	The Serum Metabolome Identifies Biomarkers of Dietary Acid Load in 2 Studies of Adults with Chronic Kidney Disease. Journal of Nutrition, 2019, 149, 578-585.	1.3	14
98	Incidence and Prognosis of Acute Kidney Diseases and Disorders Using an Integrated Approach to Laboratory Measurements in a Universal Health Care System. JAMA Network Open, 2019, 2, e191795.	2.8	73
99	Serum Metabolomic Alterations Associated with Proteinuria in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 342-353.	2.2	34
100	Serum metabolites associated with dietary protein intake: results from the Modification of Diet in Renal Disease (MDRD) randomized clinical trial. American Journal of Clinical Nutrition, 2019, 109, 517-525.	2.2	21
101	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 2019, 73, 309-315.	2.1	18
102	Validation of a Metabolite Panel for a More Accurate Estimation of Glomerular Filtration Rate Using Quantitative LC-MS/MS. Clinical Chemistry, 2019, 65, 406-418.	1.5	16
103	Measurement and Estimation of Kidney Function. , 2019, , 23-41.e3.		3
104	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes and Endocrinology,the, 2019, 7, 115-127.	5.5	199
105	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes and Endocrinology,the, 2019, 7, 128-139.	5.5	223
106	Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. American Journal of Kidney Diseases, 2019, 73, 206-217.	2.1	49
107	Metabolomic profiling to improve glomerular filtration rate estimation: a proof-of-concept study. Nephrology Dialysis Transplantation, 2019, 34, 825-833.	0.4	37
108	Measurement and Estimation of Residual Kidney Function in Patients on Dialysis. Advances in Chronic Kidney Disease, 2018, 25, 93-104.	0.6	28

#	Article	IF	Citations
109	Estimated Glomerular Filtration Rate From a Panel of Filtration Markersâ€"Hope for Increased Accuracy Beyond Measured Glomerular Filtration Rate?. Advances in Chronic Kidney Disease, 2018, 25, 67-75.	0.6	52
110	Core Assessment of Predonation Kidney Function: Clarification of the 2017 KDIGO Living Donor Guideline. American Journal of Kidney Diseases, 2018, 72, 154-155.	2.1	1
111	Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from aÂKidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2018, 93, 1281-1292.	2.6	69
112	In Reply to â€˜How Valid Are GFR Estimation Results From the CKD-EPI Databases?â€™. American Journal of Kidney Diseases, 2018, 71, 447.	2.1	0
113	Improving Carboplatin Dosing Based on EstimatedÂGFR. American Journal of Kidney Diseases, 2018, 71, 163-165.	2.1	16
114	Serum Uromodulin: A Biomarker of Long-Term Kidney Allograft Failure. American Journal of Nephrology, 2018, 47, 275-282.	1.4	31
115	Predicting timing of clinical outcomes in patientsÂwith chronic kidney disease and severely decreased glomerular filtration rate. Kidney International, 2018, 93, 1442-1451.	2.6	124
116	Performance of glomerular filtration rate estimating equations in a community-based sample of Blacks and Whites: the multiethnic study of atherosclerosis. Nephrology Dialysis Transplantation, 2018, 33, 417-425.	0.4	36
117	Comparison of glomerular filtration rate estimating equations derived from creatinine and cystatin C: validation in the Age, Gene/Environment Susceptibility-Reykjavik elderly cohort. Nephrology Dialysis Transplantation, 2018, 33, 1380-1388.	0.4	37
118	BP in Dialysis: Results of a Pilot Study. Journal of the American Society of Nephrology: JASN, 2018, 29, 307-316.	3.0	49
119	Imprecise Kidney Function Thresholds in Cancer Clinical Trials and the Potential for Harm. JNCI Cancer Spectrum, 2018, 2, pky060.	1.4	8
120	Hereditary Kidney Disease: All Family Members Are Affected. Journal of the American Society of Nephrology: JASN, 2018, 29, 2451-2452.	3.0	3
121	Serum 6-Bromotryptophan Levels Identified as a Risk Factor for CKD Progression. Journal of the American Society of Nephrology: JASN, 2018, 29, 1939-1947.	3.0	13
122	Serum metabolites are associated with all-cause mortality in chronic kidney disease. Kidney International, 2018, 94, 381-389.	2.6	42
123	The AGES-Reykjavik Study suggests that change in kidney measures is associated with subclinical brain pathology in older community-dwelling persons. Kidney International, 2018, 94, 608-615.	2.6	10
124	Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1013-1021.	2.2	23
125	Acute Kidney Injury. Annals of Internal Medicine, 2018, 168, 837.	2.0	18
126	Effects of Body Size and Composition on Sex Differences in Measured GFR in a USÂCommunity-Based Older Cohort (MESA-Kidney). American Journal of Kidney Diseases, 2018, 72, 767-770.	2.1	3

#	Article	IF	Citations
127	Biological Variability of Estimated GFR and Albuminuria in CKD. American Journal of Kidney Diseases, 2018, 72, 538-546.	2.1	62
128	Aortic stiffness and change in glomerular filtration rate and albuminuria in older people. Nephrology Dialysis Transplantation, 2017, 32, gfw050.	0.4	12
129	Urine Potassium Excretion, Kidney Failure, and Mortality in CKD. American Journal of Kidney Diseases, 2017, 69, 341-349.	2.1	66
130	B-Type Natriuretic Peptide and Cardiac Troponin I Are Associated With Adverse Outcomes in Stable Kidney Transplant Recipients. Transplantation, 2017, 101, 182-190.	0.5	10
131	Strategies for Assessing GFR and Albuminuria in the Living Kidney Donor Evaluation. Current Transplantation Reports, 2017, 4, 13-23.	0.9	9
132	Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT Trial. American Journal of Transplantation, 2017, 17, 2390-2399.	2.6	23
133	Global Cardiovascular and Renal Outcomes of Reduced GFR. Journal of the American Society of Nephrology: JASN, 2017, 28, 2167-2179.	3.0	194
134	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet, The, 2017, 390, 1888-1917.	6.3	662
135	Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in the Elderly: AGES-Kidney and MESA-Kidney. American Journal of Kidney Diseases, 2017, 70, 406-414.	2.1	50
136	Comparing Newer GFR Estimating Equations Using Creatinine and Cystatin C to the CKD-EPI Equations in Adults. American Journal of Kidney Diseases, 2017, 70, 587-589.	2.1	30
137	Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort. American Journal of Kidney Diseases, 2017, 70, 377-385.	2.1	23
138	ESRD After Heart Failure, Myocardial Infarction, or Stroke in TypeÂ2 Diabetic Patients With CKD. American Journal of Kidney Diseases, 2017, 70, 522-531.	2.1	15
139	Estimating Glomerular Filtration Rate Using Serum Creatinine. Clinical Chemistry, 2017, 63, 1161-1162.	1.5	11
140	GFR Evaluation in Living Kidney Donor Candidates. Journal of the American Society of Nephrology: JASN, 2017, 28, 1062-1071.	3.0	39
141	Albuminuria changes are associated with subsequent risk of end-stage renal disease andÂmortality. Kidney International, 2017, 91, 244-251.	2.6	104
142	Urine Fibrosis Markers and Risk of Allograft Failure in Kidney Transplant Recipients: A Case-Cohort Ancillary Study of the FAVORIT Trial. American Journal of Kidney Diseases, 2017, 69, 410-419.	2.1	49
143	Action plan for determining and monitoring the prevalence of chronic kidney disease. Kidney International Supplements, 2017, 7, 63-70.	4.6	16
144	Action plan for optimizing the design of clinical trials in chronic kidney disease. Kidney International Supplements, 2017, 7, 138-144.	4.6	19

#	Article	IF	Citations
145	Metabolomic Alterations Associated with Cause of CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1787-1794.	2.2	54
146	Summary of Kidney Disease. Transplantation, 2017, 101, 1783-1792.	0.5	225
147	A Rebuttal to â€œThe CKD Classification System in the Precision Medicine Eraâ€• Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1711-1713.	2.2	4
148	In Reply to â€˜Newer GFR Estimating Equations Require Validation in Different Populationsâ€™. American Journal of Kidney Diseases, 2017, 70, 586-587.	2.1	2
149	Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. American Journal of Nephrology, 2017, 46, 488-497.	1.4	8
150	Acute Kidney Injury. Annals of Internal Medicine, 2017, 167, ITC66.	2.0	335
151	Risk of ESRD and Mortality Associated With Change in Filtration Markers. American Journal of Kidney Diseases, 2017, 70, 551-560.	2.1	20
152	A tripartite complex of suPAR, APOL1 risk variants and Î±vÎ²3 integrin on podocytes mediates chronic kidney disease. Nature Medicine, 2017, 23, 945-953.	15.2	176
153	Filtration Markers as Predictors of ESRD and Mortality: Individual Participant Data Meta-Analysis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 69-78.	2.2	24
154	A Dynamic Predictive Model for Progression of CKD. American Journal of Kidney Diseases, 2017, 69, 514-520.	2.1	78
155	Assessment of Glomerular Filtration Rate in Health and Disease: A State of the Art Review. Clinical Pharmacology and Therapeutics, 2017, 102, 405-419.	2.3	178
156	KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation, 2017, 101, S7-S105.	0.5	308
157	Novel Filtration Markers for GFR Estimation. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2017, 28, 277-288.	0.7	10
158	Ten Years Atop the Masthead. American Journal of Kidney Diseases, 2016, 68, 825-827.	2.1	2
159	O1â€02â€02: Decline in Kidney Function and Subclinical Brain Pathologies. Alzheimer's and Dementia, 2016, 12, P173.	0.4	0
160	Serum Î²-Trace Protein and Î²2-Microglobulin as Predictors of ESRD, Mortality, and Cardiovascular Disease in Adults With CKD in the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2016, 68, 68-76.	2.1	61
161	Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis. American Journal of Kidney Diseases, 2016, 68, 392-401.	2.1	85
162	Non-GFR Determinants of Low-Molecular-Weight Serum ProteinÂFiltration Markers in CKD. American Journal of Kidney Diseases, 2016, 68, 892-900.	2.1	70

#	Article	IF	Citations
163	DASH (Dietary Approaches to Stop Hypertension) Diet and Risk of Subsequent Kidney Disease. American Journal of Kidney Diseases, 2016, 68, 853-861.	2.1	221
164	Effects of Race and Sex on Measured GFR: The Multi-Ethnic Study of Atherosclerosis. American Journal of Kidney Diseases, 2016, 68, 743-751.	2.1	40
165	C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 2016, 68, 873-881.	2.1	28
166	In Reply to â€˜Plasma Clearance of Iohexol in Hemodialysis Patients Requires Prolonged Blood Samplingâ€™. American Journal of Kidney Diseases, 2016, 67, 811-812.	2.1	3
167	Managing Chronic Kidney Disease in Older Peopleâ€”Reply. JAMA - Journal of the American Medical Association, 2016, 315, 307.	3.8	4
168	Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure. JAMA - Journal of the American Medical Association, 2016, 315, 164.	3.8	450
169	Progression to Stage 4 chronic kidney disease and death, acute kidney injury and hospitalization risk: a retrospective cohort study. Nephrology Dialysis Transplantation, 2016, 31, 1122-1130.	0.4	19
170	Past Decline Versus Current eGFR and Subsequent ESRD Risk. Journal of the American Society of Nephrology: JASN, 2016, 27, 2447-2455.	3.0	78
171	Candidate Surrogate End Points for ESRD after AKI. Journal of the American Society of Nephrology: JASN, 2016, 27, 2851-2859.	3.0	47
172	CKD and Diabetes: What Can We Learn From Their Similarities and Differences?. American Journal of Kidney Diseases, 2016, 67, 360-363.	2.1	11
173	Estimating residual kidney function in dialysis patients without urine collection. Kidney International, 2016, 89, 1099-1110.	2.6	71
174	Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. American Journal of Kidney Diseases, 2016, 68, 277-286.	2.1	19
175	GFR as the â€œGold Standardâ€: Estimated, Measured, and True. American Journal of Kidney Diseases, 2016, 67, 9-12.	2.1	78
176	Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate. New England Journal of Medicine, 2016, 374, 411-421.	13.9	354
177	Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial. Journal of the American Society of Nephrology: JASN, 2016, 27, 2109-2121.	3.0	24
178	Relationship of dietary phosphate intake with risk of end-stage renal disease and mortality in chronic kidney disease stages 3â€“5: The Modification of Diet in Renal Disease Study. Kidney International, 2016, 89, 176-184.	2.6	64
179	Prevalence and complications of chronic kidney disease in a representative elderly population in Iceland. Nephrology Dialysis Transplantation, 2016, 31, 439-447.	0.4	17
180	Biomarkers of Vitamin D Status and Risk of ESRD. American Journal of Kidney Diseases, 2016, 67, 235-242.	2.1	30

#	Article	IF	Citations
181	GFR Estimation Using Î²-Trace Protein and Î²2-Microglobulin inÂCKD. American Journal of Kidney Diseases, 2016, 67, 40-48.	2.1	121
182	A Metabolome-Wide Association Study of Kidney Function and Disease in the General Population. Journal of the American Society of Nephrology: JASN, 2016, 27, 1175-1188.	3.0	159
183	Associations between arterial stiffness, depressive symptoms and cerebral small vessel disease: cross-sectional findings from the AGES-Reykjavik Study. Journal of Psychiatry and Neuroscience, 2016, 41, 162-168.	1.4	48
184	Filtration Markers as Predictors of ESRD and Mortality in Southwestern American Indians With Type 2 Diabetes. American Journal of Kidney Diseases, 2015, 66, 75-83.	2.1	43
185	Cause of Death in Patients With Diabetic CKD Enrolled in theÂTrial to Reduce Cardiovascular Events With Aranesp TherapyÂ(TREAT). American Journal of Kidney Diseases, 2015, 66, 429-440.	2.1	29
186	Chronic Kidney Disease in Older People. JAMA - Journal of the American Medical Association, 2015, 314, 557.	3.8	82
187	Comparing GFR Estimating Equations Using Cystatin C and Creatinine in Elderly Individuals. Journal of the American Society of Nephrology: JASN, 2015, 26, 1982-1989.	3.0	132
188	Glomerular Filtration Rate and Albuminuria for Detection and Staging of Acute and Chronic Kidney Disease in Adults. JAMA - Journal of the American Medical Association, 2015, 313, 837.	3.8	431
189	Introducing the AJKD Atlas of Renal Pathology II. American Journal of Kidney Diseases, 2015, 66, 179-180.	2.1	2
190	Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus. American Heart Journal, 2015, 170, 322-329.e4.	1.2	32
191	Aortic Stiffness and Kidney Disease in an Elderly Population. American Journal of Nephrology, 2015, 41, 320-328.	1.4	19
192	Change in Multiple Filtration Markers and Subsequent Risk of Cardiovascular Disease and Mortality. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 941-948.	2.2	16
193	A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. American Journal of Kidney Diseases, 2015, 66, 602-612.	2.1	210
194	A Meta-analysis of the Association of Estimated GFR, Albuminuria, Age, Race, and Sex With Acute Kidney Injury. American Journal of Kidney Diseases, 2015, 66, 591-601.	2.1	138
195	Long-term medical risks to the living kidney donor. Nature Reviews Nephrology, 2015, 11, 411-419.	4.1	63
196	ESRD and Death after Heart Failure in CKD. Journal of the American Society of Nephrology: JASN, 2015, 26, 715-722.	3.0	36
197	Serum Fibroblast Growth Factor-23 Is Associated with Incident Kidney Disease. Journal of the American Society of Nephrology: JASN, 2015, 26, 192-200.	3.0	56
198	Using Glomerular Filtration Rate Estimating Equations: Clinical and Laboratory Considerations. Clinical Chemistry, 2015, 61, 1226-1229.	1.5	9

#	Article	IF	Citations
199	Midlife Blood Pressure and Late-Life GFR and Albuminuria: An Elderly General Population Cohort. American Journal of Kidney Diseases, 2015, 66, 240-248.	2.1	28
200	Lifetime Risk of Stage 3â€“5 CKD in a Community-Based Sample in Iceland. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1575-1584.	2.2	23
201	Plasma Iohexol Clearance for Assessing Residual Kidney Function in Dialysis Patients. American Journal of Kidney Diseases, 2015, 66, 728-730.	2.1	13
202	Segmental Kidney Volumes Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging and Their Association With CKD in Older People. American Journal of Kidney Diseases, 2015, 65, 41-48.	2.1	23
203	Mediation Analysis of Aortic Stiffness and Renal Microvascular Function. Journal of the American Society of Nephrology: JASN, 2015, 26, 1181-1187.	3.0	97
204	Glomerular filtration rate estimation using cystatin C alone or combined with creatinine as a confirmatory test. Nephrology Dialysis Transplantation, 2014, 29, 1195-1203.	0.4	76
205	Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. Kidney International, 2014, 86, 819-827.	2.6	70
206	Utility and Validity of Estimated GFRâ€“Based Surrogate Time-to-Event End Points in CKD: A Simulation Study. American Journal of Kidney Diseases, 2014, 64, 867-879.	2.1	59
207	GFR Decline as an Alternative End Point to Kidney Failure in Clinical Trials: A Meta-analysis of Treatment Effects From 37 Randomized Trials. American Journal of Kidney Diseases, 2014, 64, 848-859.	2.1	109
208	GFR Decline and Subsequent Risk of Established Kidney Outcomes: A Meta-analysis of 37 Randomized Controlled Trials. American Journal of Kidney Diseases, 2014, 64, 860-866.	2.1	108
209	GFR Decline as an End Point for Clinical Trials in CKD: AÂScientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration. American Journal of Kidney Diseases, 2014, 64, 821-835.	2.1	430
210	BP, Cardiovascular Disease, and Death in the Folic Acid for Vascular Outcome Reduction in Transplantation Trial. Journal of the American Society of Nephrology: JASN, 2014, 25, 1554-1562.	3.0	60
211	Urinary sodium excretion and kidney failure in nondiabetic chronic kidney disease. Kidney International, 2014, 86, 582-588.	2.6	65
212	Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality. JAMA - Journal of the American Medical Association, 2014, 311, 2518.	3.8	760
213	Staging and Management of Chronic Kidney Disease. , 2014, , 458-466.		7
214	Early Change in Proteinuria as a Surrogate End Point for Kidney Disease Progression: An Individual Patient Meta-analysis. American Journal of Kidney Diseases, 2014, 64, 74-85.	2.1	104
215	Estimation of GFR in South Asians: A Study From the General Population in Pakistan. American Journal of Kidney Diseases, 2014, 63, 49-58.	2.1	69
216	Assessment of Glomerular Filtration Rate in Acute and Chronic Settings. , 2014, , 26-32.		6

#	Article	IF	Citations
217	In Reply to â€˜Creatinine-Based GFR Estimating Equations in Kidney Transplant Recipientsâ€™ and â€˜Assessing Kidney Function in Transplant Recipients: Time to Work Together and Address theÂMost Relevant Questionsâ€™. American Journal of Kidney Diseases, 2014, 64, 819.	2.1	6
218	Risk of End-Stage Renal Disease and Death After Cardiovascular Events in Chronic Kidney Disease. Circulation, 2014, 130, 458-465.	1.6	57
219	Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Nonâ€“Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT). American Journal of Kidney Diseases, 2014, 63, 244-250.	2.1	55
220	Cystatin C for Glomerular Filtration Rate Estimation: Coming of Age. Clinical Chemistry, 2014, 60, 916-919.	1.5	28
221	CKD Stage at Nephrology Referral and Factors Influencing the Risks of ESRD and Death. American Journal of Kidney Diseases, 2014, 63, 928-936.	2.1	37
222	Performance of Creatinine-Based GFR Estimating Equations inÂSolid-Organ Transplant Recipients. American Journal of Kidney Diseases, 2014, 63, 1007-1018.	2.1	103
223	GFR Estimation: From Physiology to Public Health. American Journal of Kidney Diseases, 2014, 63, 820-834.	2.1	427
224	Risk Prediction Models for Patients With Chronic Kidney Disease. Annals of Internal Medicine, 2013, 158, 596.	2.0	180
225	Cystatin C versus Creatinine in Determining Risk Based on Kidney Function. New England Journal of Medicine, 2013, 369, 932-943.	13.9	729
226	Within-Person Variability in Kidney Measures. American Journal of Kidney Diseases, 2013, 61, 716-722.	2.1	55
227	Cohort Profile: The Chronic Kidney Disease Prognosis Consortium. International Journal of Epidemiology, 2013, 42, 1660-1668.	0.9	69
228	Calibration of Cystatin C in the National Health and Nutrition Examination Surveys (NHANES). American Journal of Kidney Diseases, 2013, 61, 353-354.	2.1	21
229	Effect of Protein Restriction on Serum and Urine Phosphate in the Modification of Diet in Renal Disease (MDRD) Study. American Journal of Kidney Diseases, 2013, 61, 1045-1046.	2.1	31
230	Influence of Urine Creatinine Concentrations on the Relation of Albumin-Creatinine Ratio With Cardiovascular Disease Events: The Multi-Ethnic Study of Atherosclerosis (MESA). American Journal of Kidney Diseases, 2013, 62, 722-729.	2.1	16
231	Novel Filtration Markers as Predictors of All-Cause and Cardiovascular Mortality in US Adults. American Journal of Kidney Diseases, 2013, 62, 42-51.	2.1	67
232	Definition and Classification of Kidney Diseases. American Journal of Kidney Diseases, 2013, 61, 686-688.	2.1	68
233	Trends in the Prevalence of Reduced GFR in the United States: A Comparison of Creatinine- and Cystatin Câ”Based Estimates. American Journal of Kidney Diseases, 2013, 62, 253-260.	2.1	94
234	Evolving importance of kidney disease: from subspecialty to global health burden. Lancet, The, 2013, 382, 158-169.	6.3	874

#	Article	IF	Citations
235	Con: Should we abandon the use of the MDRD equation in favour of the CKD-EPI equation?. Nephrology Dialysis Transplantation, 2013, 28, 1396-1403.	0.4	53
236	Pro: Estimating GFR using the chronic kidney disease epidemiology collaboration (CKD-EPI) 2009 creatinine equation: the time for change is now. Nephrology Dialysis Transplantation, 2013, 28, 1390-1396.	0.4	29
237	Comparison of Serum Concentrations of Î²-Trace Protein, Î²2-Microglobulin, Cystatin C, and Creatinine in the US Population. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 584-592.	2.2	57
238	Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ, The, 2013, 346, f324-f324.	3.0	317
239	The Kidney Disease Improving Global Outcomes (KDIGO) Guideline Update for Chronic Kidney Disease: Evolution not Revolution. Clinical Chemistry, 2013, 59, 462-465.	1.5	90
240	Filtration Markers May Have Prognostic Value Independent of Glomerular Filtration Rate. Journal of the American Society of Nephrology: JASN, 2012, 23, 351-359.	3.0	76
241	Comparison of Risk Prediction Using the CKD-EPI Equation and the MDRD Study Equation for Estimated Glomerular Filtration Rate. JAMA - Journal of the American Medical Association, 2012, 307, 1941-51.	3.8	810
242	SerumÎ²-Trace Protein and Risk of Mortality in Incident Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1435-1445.	2.2	25
243	Estimating Glomerular Filtration Rate Using the Chronic Kidney Disease-Epidemiology Collaboration Creatinine Equation. Circulation: Heart Failure, 2012, 5, 303-306.	1.6	25
244	Estimating Equations for Glomerular Filtration Rate in the Era of Creatinine Standardization. Annals of Internal Medicine, 2012, 156, 785.	2.0	346
245	Accuracy of a GFR Estimating Equation Over Time in People With a Wide Range of Kidney Function. American Journal of Kidney Diseases, 2012, 60, 217-224.	2.1	46
246	Clinical Risk Implications of the CKD Epidemiology Collaboration (CKD-EPI) Equation Compared With the Modification of Diet in Renal Disease (MDRD) Study Equation for Estimated GFR. American Journal of Kidney Diseases, 2012, 60, 241-249.	2.1	79
247	Cognitive Dysfunction and Depression in Adult Kidney Transplant Recipients: Baseline Findings from the FAVORIT Ancillary Cognitive Trial (FACT). , 2012, 22, 268-276.e3.		30
248	A Decade After the KDOQI CKD Guidelines. American Journal of Kidney Diseases, 2012, 60, 683-685.	2.1	27
249	Chronic kidney disease. Lancet, The, 2012, 379, 165-180.	6.3	1,463
250	Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C. New England Journal of Medicine, 2012, 367, 20-29.	13.9	3,072
251	Staying Put, But Not Standing Still. American Journal of Kidney Diseases, 2012, 59, 1-3.	2.1	136
252	Fibroblast Growth Factor 23 and CKD Prognosis. American Journal of Kidney Diseases, 2012, 59, 607-610.	2.1	1

#	Article	IF	Citations
253	In Reply to â€˜What Dominates Living Donor Kidney Transplantation: Altruism or Loss of Dignity?â€™. American Journal of Kidney Diseases, 2012, 59, 317.	2.1	1
254	Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Annals of Internal Medicine, 2012, 156, 785-95.	2.0	221
255	Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney International, 2011, 79, 1341-1352.	2.6	759
256	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney International, 2011, 79, 1331-1340.	2.6	609
257	Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. American Heart Journal, 2011, 162, 548-554.	1.2	150
258	Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular filtration rate in multiple ethnicities. Kidney International, 2011, 79, 555-562.	2.6	413
259	Classification of Chronic Kidney Disease: A Step Forward. Annals of Internal Medicine, 2011, 154, 65.	2.0	28
260	Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Cystatin C Equations for Estimating GFR With Standardized Serum Cystatin C Values. American Journal of Kidney Diseases, 2011, 58, 682-684.	2.1	185
261	Association Between Cardiac Biomarkers and the Development of ESRD in Patients With Type 2 Diabetes Mellitus, Anemia, and CKD. American Journal of Kidney Diseases, 2011, 58, 717-728.	2.1	123
262	Living Donor Kidney Transplantation in the United Statesâ€”Looking Back, Looking Forward. American Journal of Kidney Diseases, 2011, 58, 343-348.	2.1	42
263	Level and Determinants of Kidney Function in a South Asian Population in Pakistan. American Journal of Kidney Diseases, 2011, 58, 764-772.	2.1	31
264	Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients. Circulation, 2011, 123, 1763-1770.	1.6	171
265	A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure. JAMA - Journal of the American Medical Association, 2011, 305, 1553.	3.8	927
266	Equations to Estimate Creatinine Excretion Rate. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 184-191.	2.2	166
267	Long-Term Viral Negativity After Interferon for Chronic Hepatitis C Virus Infection in Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2226-2234.	2.2	20
268	Estimated GFR, Albuminuria, and Complications of Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2011, 22, 2322-2331.	3.0	88
269	Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset. Nephrology Dialysis Transplantation, 2011, 26, 848-857.	0.4	22
270	Changes in dietary protein intake has no effect on serum cystatin C levels independent of the glomerular filtration rate. Kidney International, 2011, 79, 471-477.	2.6	142

#	Article	IF	Citations
271	Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney International, 2011, 80, 93-104.	2.6	676
272	Cystatin C Identifies Chronic Kidney Disease Patients at Higher Risk for Complications. Journal of the American Society of Nephrology: JASN, 2011, 22, 147-155.	3.0	189
273	Advances in glomerular filtration rate-estimating equations. Current Opinion in Nephrology and Hypertension, 2010, 19, 298-307.	1.0	56
274	Estimating GFR Using the CKD Epidemiology Collaboration (CKD-EPI) Creatinine Equation: More Accurate GFR Estimates, Lower CKD Prevalence Estimates, and Better Risk Predictions. American Journal of Kidney Diseases, 2010, 55, 622-627.	2.1	773
275	Imprecision of Urinary Iothalamate Clearance as a Gold-Standard Measure of GFR Decreases the Diagnostic Accuracy of Kidney Function Estimating Equations. American Journal of Kidney Diseases, 2010, 56, 39-49.	2.1	115
276	Comparative Performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study Equations for Estimating GFR Levels Above 60 mL/min/1.73 m2. American Journal of Kidney Diseases, 2010, 56, 486-495.	2.1	507
277	Obesity, Glomerular Hyperfiltration, and the Surface Area Correction. American Journal of Kidney Diseases, 2010, 56, 255-258.	2.1	43
278	Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 2010, 363, 1146-1155.	13.9	433
279	Effect of intra-dialytic, low-intensity strength training on functional capacity in adult haemodialysis patients: a randomized pilot trial. Nephrology Dialysis Transplantation, 2010, 25, 1936-1943.	0.4	165
280	Both low muscle mass and low fat are associated with higher all-cause mortality in hemodialysis patients. Kidney International, 2010, 77, 624-629.	2.6	149
281	Clinical Impact of Reporting Estimated Glomerular Filtration Rates. Clinical Chemistry, 2010, 56, 1381-1383.	1.5	7
282	Development and validation of GFR-estimating equations using diabetes, transplant and weight. Nephrology Dialysis Transplantation, 2010, 25, 449-457.	0.4	111
283	Chronic kidney disease, diabetes, and hypertension: what's in a name?. Kidney International, 2010, 78, 19-22.	2.6	50
284	Filtration Markers in Acute Kidney Injury. American Journal of Kidney Diseases, 2010, 56, 619-622.	2.1	7
285	Assessment of Renal Function. , 2010, , 31-38.		13
286	Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet, The, 2010, 375, 2073-2081.	6.3	3,277
287	Impact of reporting estimated glomerular filtration rate: it's not just about us. Kidney International, 2009, 76, 245-247.	2.6	13
288	Interferon for Hepatitis C Virus in Hemodialysisâ€"an Individual Patient Meta-analysis of Factors Associated with Sustained Virological Response. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1449-1458.	2.2	24

#	Article	IF	Citations
289	Key Comorbid Conditions that Are Predictive of Survival among Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1818-1826.	2.2	69
290	Current Status and Future Perspectives for CKD Testing. American Journal of Kidney Diseases, 2009, 53, S17-S26.	2.1	54
291	Conceptual Model of CKD: Applications and Implications. American Journal of Kidney Diseases, 2009, 53, S4-S16.	2.1	139
292	Effect of a Very Low-Protein Diet on Outcomes: Long-term Follow-up of the Modification of Diet in Renal Disease (MDRD) Study. American Journal of Kidney Diseases, 2009, 53, 208-217.	2.1	210
293	Baseline Characteristics of Participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. American Journal of Kidney Diseases, 2009, 53, 121-128.	2.1	44
294	Albuminuria, Cognitive Functioning, and White Matter Hyperintensities in Homebound Elders. American Journal of Kidney Diseases, 2009, 53, 438-447.	2.1	141
295	Comprehensive Public Health Strategies for Preventing the Development, Progression, and Complications of CKD: Report of an Expert Panel Convened by the Centers for Disease Control and Prevention. American Journal of Kidney Diseases, 2009, 53, 522-535.	2.1	168
296	Uric Acid and Long-term Outcomes in CKD. American Journal of Kidney Diseases, 2009, 53, 796-803.	2.1	359
297	Comparison of Drug Dosing Recommendations Based on Measured GFR and Kidney Function Estimating Equations. American Journal of Kidney Diseases, 2009, 54, 33-42.	2.1	292
298	Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 2009, 54, 59-69.	2.1	60
299	Nephrotic Syndrome in Diabetic Kidney Disease: An Evaluation and Update of the Definition. American Journal of Kidney Diseases, 2009, 54, 840-849.	2.1	33
300	A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2009, 361, 2019-2032.	13.9	2,110
301	A New Equation to Estimate Glomerular Filtration Rate. Annals of Internal Medicine, 2009, 150, 604.	2.0	19,025
302	Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney International, 2009, 75, 652-660.	2.6	590
303	Measured GFR as a Confirmatory Test for Estimated GFR. Journal of the American Society of Nephrology: JASN, 2009, 20, 2305-2313.	3.0	486
304	Method of Glomerular Filtration Rate Estimation Affects Prediction of Mortality Risk. Journal of the American Society of Nephrology: JASN, 2009, 20, 2214-2222.	3.0	119
305	The CKD-EPI Equation and MDRD Study Equation Find Similar Prevalence of Chronic Kidney Disease in Asian Populations. Annals of Internal Medicine, 2009, 151, 893.	2.0	0
306	Prevalence of ICD-9-CM codes for chronic kidney disease in individuals with cardiovascular disease risk factors. Journal of Nephrology, 2009, 22, 523-33.	0.9	1

#	Article	IF	Citations
307	The Relationship Between Nontraditional Risk Factors and Outcomes in Individuals With Stage 3 to 4 CKD. American Journal of Kidney Diseases, 2008, 51, 212-223.	2.1	131
308	Interferon Treatment in Hemodialysis Patients With Chronic Hepatitis C Virus Infection: A Systematic Review of the Literature and Meta-analysis of Treatment Efficacy and Harms. American Journal of Kidney Diseases, 2008, 51, 263-277.	2.1	123
309	Estimating GFR Using Serum Cystatin C Alone and in Combination With Serum Creatinine: A Pooled Analysis of 3,418 Individuals With CKD. American Journal of Kidney Diseases, 2008, 51, 395-406.	2.1	944
310	Serum Cystatin C in the United States: The Third National Health and Nutrition Examination Survey (NHANES III). American Journal of Kidney Diseases, 2008, 51, 385-394.	2.1	143
311	CKD in the Elderlyâ€"Old Questions and New Challenges: World Kidney Day 2008. American Journal of Kidney Diseases, 2008, 51, 353-357.	2.1	51
312	Cystatin C and Creatinine in an HIV Cohort: The Nutrition for Healthy Living Study. American Journal of Kidney Diseases, 2008, 51, 914-924.	2.1	50
313	Waist-to-Hip Ratio, Body Mass Index, and Subsequent Kidney Disease and Death. American Journal of Kidney Diseases, 2008, 52, 29-38.	2.1	224
314	Waist-to-Hip Ratio and Body Mass Index as Risk Factors for Cardiovascular Events in CKD. American Journal of Kidney Diseases, 2008, 52, 49-57.	2.1	133
315	Disordered Mineral Metabolism in Hemodialysis Patients: An Analysis of Cumulative Effects in the Hemodialysis (HEMO) Study. American Journal of Kidney Diseases, 2008, 52, 531-540.	2.1	100
316	A Comparison of Change in Measured and Estimated Glomerular Filtration Rate in Patients with Nondiabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1332-1338.	2.2	61
317	A Framework and Key Research Questions in AKI Diagnosis and Staging in Different Environments. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 864-868.	2.2	96
318	Association between Serum Î²2-Microglobulin Level and Infectious Mortality in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 69-77.	2.2	86
319	Patient Awareness of Chronic Kidney Disease. Archives of Internal Medicine, 2008, 168, 2268.	4.3	251
320	Uric Acid and Incident Kidney Disease in the Community. Journal of the American Society of Nephrology: JASN, 2008, 19, 1204-1211.	3.0	387
321	Association of physical activity with mortality in chronic kidney disease. Journal of Nephrology, 2008, 21, 243-52.	0.9	22
322	Evaluation of the Modification of Diet in Renal Disease Study Equation in a Large Diverse Population. Journal of the American Society of Nephrology: JASN, 2007, 18, 2749-2757.	3.0	498
323	Chronic Kidney Disease: Common, Harmful and Treatable â€“ World Kidney Day 2007. American Journal of Nephrology, 2007, 27, 108-112.	1.4	43
324	Use of albumin creatinine ratio and urine albumin concentration as a screening test for albuminuria in an Indo-Asian population. Nephrology Dialysis Transplantation, 2007, 22, 2194-2200.	0.4	73

#	Article	IF	Citations
325	Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 1959-1965.	3.0	154
326	Lowest Systolic Blood Pressure Is Associated with Stroke in Stages 3 to 4 Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 960-966.	3.0	93
327	Prevalence of Chronic Kidney Disease in the United States. JAMA - Journal of the American Medical Association, 2007, 298, 2038.	3.8	4,121
328	Chronic kidney disease is common: What do we do next?. Nephrology Dialysis Transplantation, 2007, 23, 1122-1125.	0.4	48
329	Cystatin C as a Risk Factor for Outcomes in Chronic Kidney Disease. Annals of Internal Medicine, 2007, 147, 19.	2.0	168
330	Cardiovascular Disease and Subsequent Kidney Disease. Archives of Internal Medicine, 2007, 167, 1130.	4.3	201
331	Agreement of self-reported comorbid conditions with medical and physician reports varied by disease among end-stage renal disease patients. Journal of Clinical Epidemiology, 2007, 60, 634-642.	2.4	95
332	Inflammation and Inverse Associations of Body Mass Index and Serum Creatinine With Mortality in Hemodialysis Patients. , 2007, 17, 372-380.		39
333	Expressing the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate with Standardized Serum Creatinine Values. Clinical Chemistry, 2007, 53, 766-772.	1.5	1,587
334	Role of Adipose Tissue in Determining Muscle Mass in Patients With Chronic Kidney Disease. , 2007, 17, 314-322.		20
335	The Framingham Predictive Instrument in Chronic Kidney Disease. Journal of the American College of Cardiology, 2007, 50, 217-224.	1.2	285
336	The Challenges of the Next 5 Years. American Journal of Kidney Diseases, 2007, 49, 1-2.	2.1	151
337	CKD: Common, Harmful, and Treatableâ€"World Kidney Day 2007. American Journal of Kidney Diseases, 2007, 49, 175-179.	2.1	63
338	Early, Intermediate, and Long-Term Risk Factors for Mortality in Incident Dialysis Patients: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. American Journal of Kidney Diseases, 2007, 49, 831-840.	2.1	37
339	Impact of Creatinine Calibration on Performance of GFR Estimating Equations in a Pooled Individual Patient Database. American Journal of Kidney Diseases, 2007, 50, 21-35.	2.1	198
340	Improving Practice: Reporting Quality Improvement Activities. American Journal of Kidney Diseases, 2007, 50, 5-7.	2.1	6
341	Body Mass Index and Mortality in CKD. American Journal of Kidney Diseases, 2007, 50, 404-411.	2.1	61
342	Testing for Chronic Kidney Disease: A Position Statement From the National Kidney Foundation. American Journal of Kidney Diseases, 2007, 50, 169-180.	2.1	283

#	Article	IF	Citations
343	Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: An Overview. American Journal of Kidney Diseases, 2007, 50, 349-353.	2.1	3
344	Calibration of Serum Creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988-1994, 1999-2004. American Journal of Kidney Diseases, 2007, 50, 918-926.	2.1	278
345	Assessing Kidney Function â€" Measured and Estimated Glomerular Filtration Rate. New England Journal of Medicine, 2006, 354, 2473-2483.	13.9	2,528
346	Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncology, The, 2006, 7, 735-740.	5.1	1,456
347	Which Antihypertensive Agents in Chronic Kidney Disease?. Annals of Internal Medicine, 2006, 144, 213.	2.0	12
348	Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate. Annals of Internal Medicine, 2006, 145, 247-254.	2.0	4,606
349	Cerebrovascular Disease in Maintenance Hemodialysis Patients: Results of the HEMO Study. American Journal of Kidney Diseases, 2006, 47, 131-138.	2.1	85
350	Cardiovascular Outcomes and All-Cause Mortality: Exploring the Interaction Between CKD and Cardiovascular Disease. American Journal of Kidney Diseases, 2006, 48, 392-401.	2.1	265
351	Effect of Dietary Protein Restriction on the Progression of Kidney Disease: Long-Term Follow-Up of the Modification of Diet in Renal Disease (MDRD) Study. American Journal of Kidney Diseases, 2006, 48, 879-888.	2.1	143
352	Relationship Between Homocysteine and Mortality in Chronic Kidney Disease. Circulation, 2006, 113, 1572-1577.	1.6	53
353	Adiponectin and Mortality in Patients with Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 2599-2606.	3.0	254
354	Automatic Reporting of Estimated Glomerular Filtration Rateâ€"Just What the Doctor Ordered. Clinical Chemistry, 2006, 52, 2188-2193.	1.5	58
355	Response to Letter Regarding Article, â€œRelationship Between Homocysteine and Mortality in Chronic Kidney Diseaseâ€, Circulation, 2006, 114, .	1.6	0
356	Clinical Practice Guidelines in nephrologyâ€"for worse or for better. Nephrology Dialysis Transplantation, 2006, 21, 1145-1153.	0.4	25
357	Serum Î²-2 Microglobulin Levels Predict Mortality in Dialysis Patients: Results of the HEMO Study. Journal of the American Society of Nephrology: JASN, 2006, 17, 546-555.	3.0	393
358	Effect of Dietary Protein Intake on Serum Total CO2 Concentration in Chronic Kidney Disease: Modification of Diet in Renal Disease Study Findings. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 52-57.	2.2	51
359	Surrogate End Points for Clinical Trials of Kidney Disease Progression. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 874-884.	2.2	116
360	Recommendations for Improving Serum Creatinine Measurement: A Report from the Laboratory Working Group of the National Kidney Disease Education Program. Clinical Chemistry, 2006, 52, 5-18.	1.5	1,057

#	Article	IF	Citations
361	The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study. Annals of Internal Medicine, 2005, 142, 342.	2.0	456
362	The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney International, 2005, 67, 265-271.	2.6	89
363	Homocysteine in chronic kidney disease: Effect of low protein diet and repletion with B vitamins. Kidney International, 2005, 67, 1539-1546.	2.6	32
364	Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International, 2005, 67, 2089-2100.	2.6	2,836
365	C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney International, 2005, 68, 766-772.	2.6	329
366	Variation in the serum creatinine assay calibration: A practical application to glomerular filtration rate estimation. Kidney International, 2005, 68, 1884-1887.	2.6	126
367	Relationship of Phosphorus and Calcium-Phosphorus Product With Mortality in CKD. American Journal of Kidney Diseases, 2005, 46, 455-463.	2.1	113
368	Association Between Body Mass Index and CKD in Apparently Healthy Men. American Journal of Kidney Diseases, 2005, 46, 871-880.	2.1	406
369	Proteinuria in South Asian children: prevalence and determinants. Pediatric Nephrology, 2005, 20, 1458-1465.	0.9	30
370	An Editorial Update: What Level of Blood Pressure Control in Chronic Kidney Disease?. Annals of Internal Medicine, 2005, 143, 79.	2.0	8
371	Low Rates of Testing and Diagnostic Codes Usage in a Commercial Clinical Laboratory: Evidence for Lack of Physician Awareness of Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 2439-2448.	3.0	126
372	High Lipoprotein(a) Levels and Small Apolipoprotein(a) Size Prospectively Predict Cardiovascular Events in Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2005, 16, 1794-1802.	3.0	78
373	General Practitionersâ€™ Approach to Hypertension in Urban Pakistan. Circulation, 2005, 111, 1278-1283.	1.6	66
374	Children in South Asia Have Higher Body Massâ€“Adjusted Blood Pressure Levels Than White Children in the United States. Circulation, 2005, 111, 1291-1297.	1.6	138
375	Serum Creatinine as Marker of Kidney Function in South Asians: A Study of Reduced GFR in Adults in Pakistan. Journal of the American Society of Nephrology: JASN, 2005, 16, 1413-1419.	3.0	101
376	Comparing the Risk for Death with Peritoneal Dialysis and Hemodialysis in a National Cohort of Patients with Chronic Kidney Disease. Annals of Internal Medicine, 2005, 143, 174.	2.0	271
377	Effects of Anemia and Left Ventricular Hypertrophy on Cardiovascular Disease in Patients with Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 1803-1810.	3.0	180
378	Anemia as a Risk Factor for Cardiovascular Disease and All-Cause Mortality in Diabetes: The Impact of Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 3403-3410.	3.0	272

#	Article	IF	Citations
379	Glycosylated Hemoglobin and Mortality in Patients with Nondiabetic Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 3411-3417.	3.0	51
380	Chronic Kidney Disease in the Elderly â€" How to Assess Risk. New England Journal of Medicine, 2005, 352, 2122-2124.	13.9	116
381	Rationaleâ€"Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal, 2005, 149, 408-413.	1.2	115
382	Factors associated with lipoprotein(a) in chronic kidney disease. American Journal of Kidney Diseases, 2005, 45, 28-38.	2.1	15
383	Chronic Kidney Disease as a Risk Factor for Cardiovascular Disease and All-Cause Mortality: A Pooled Analysis of Community-Based Studies. Journal of the American Society of Nephrology: JASN, 2004, 15, 1307-1315.	3.0	1,072
384	Frequency of Patient-Physician Contact and Patient Outcomes in Hemodialysis Care. Journal of the American Society of Nephrology: JASN, 2004, 15, 210-218.	3.0	55
385	Frequency of Sit-Down Patient Care Rounds, Attainment of Clinical Performance Targets, Hospitalization, and Mortality in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2004, 15, 3144-3153.	3.0	30
386	Predicting 1 year mortality in an outpatient haemodialysis population: a comparison of comorbidity instruments. Nephrology Dialysis Transplantation, 2004, 19, 413-420.	0.4	91
387	Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney International, 2004, 65, 2380-2389.	2.6	441
388	Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease. American Journal of Kidney Diseases, 2004, 43, 607-616.	2.1	196
389	Restless legs symptoms among incident dialysis patients: Association with lower quality of life and shorter survival. American Journal of Kidney Diseases, 2004, 43, 900-909.	2.1	189
390	Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. American Journal of Kidney Diseases, 2004, 44, 198-206.	2.1	243
391	Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy. American Journal of Cardiology, 2004, 94, 337-339.	0.7	21
392	Estimation of glomerular filtration rates before and after orthotopic liver transplantation: Evaluation of current equations. Liver Transplantation, 2004, 10, 301-309.	1.3	303
393	Clinical Implications of Estimating Equations for Glomerular Filtration Rate. Annals of Internal Medicine, 2004, 141, 959.	2.0	90
394	Clinical practice guidelines for chronic kidney disease in adults: Part I. Definition, disease stages, evaluation, treatment, and risk factors. American Family Physician, 2004, 70, 869-76.	0.1	95
395	How strong are patients' preferences in choices between dialysis modalities and doses?. American Journal of Kidney Diseases, 2004, 44, 695-705.	2.1	16
396	Clinical practice guidelines for chronic kidney disease in adults: Part II. Glomerular filtration rate, proteinuria, and other markers. American Family Physician, 2004, 70, 1091-7.	0.1	48

#	Article	IF	Citations
397	Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third national health and nutrition examination survey. American Journal of Kidney Diseases, 2003, 41, 1-12.	2.1	2,193
398	Comorbidity and its change predict survival in incident dialysis patients. American Journal of Kidney Diseases, 2003, 41, 149-161.	2.1	87
399	Demographics and trends in overweight and obesity in patients at time of kidney transplantation. American Journal of Kidney Diseases, 2003, 41, 480-487.	2.1	227
400	High urine volume and low urine osmolality are risk factors for faster progression of renal disease. American Journal of Kidney Diseases, 2003, 41, 962-971.	2.1	121
401	Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. American Journal of Kidney Diseases, 2003, 42, 44-52.	2.1	157
402	Lipoprotein(a) and prevalent cardiovascular disease in a dialysis population: the choices for healthy outcomes in caring for ESRD (CHOICE) study. American Journal of Kidney Diseases, 2003, 42, 108-116.	2.1	21
403	Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). American Journal of Kidney Diseases, 2003, 42, 617-622.	2.1	395
404	Should the K/DOQI definition of chronic kidney disease be changed?. American Journal of Kidney Diseases, 2003, 42, 626-630.	2.1	13
405	Constructing a database of individual clinical trials for longitudinal analysis. Contemporary Clinical Trials, 2003, 24, 324-340.	2.0	22
406	Ethnic differences and determinants of proteinuria among South Asian subgroups in Pakistan. Kidney International, 2003, 64, 1437-1444.	2.6	27
407	Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney International, 2003, 63, 1121-1129.	2.6	390
408	THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Traditional Cardiac Risk Factors in Individuals with Chronic Kidney Disease. Seminars in Dialysis, 2003, 16, 118-127.	0.7	85
409	Dialysis Membrane and Modality in Acute Renal Failure: Understanding Discordant Meta-Analyses. Seminars in Dialysis, 2003, 16, 356-360.	0.7	27
410	Kidney Disease as a Risk Factor for Development of Cardiovascular Disease. Circulation, 2003, 108, 2154-2169.	1.6	3,082
411	Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis. Annals of Internal Medicine, 2003, 139, 244.	2.0	945
412	Bias in Assessment of Health-Related Quality of Life in a Hemodialysis Population: A Comparison of Self-Administered and Interviewer-Administered Surveys in the HEMO Study. Journal of the American Society of Nephrology: JASN, 2003, 14, 2132-2141.	3.0	50
413	Effects of High-Flux Hemodialysis on Clinical Outcomes: Results of the HEMO Study. Journal of the American Society of Nephrology: JASN, 2003, 14, 3251-3263.	3.0	238
414	The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrology Dialysis Transplantation, 2003, 18, 2047-2053.	0.4	143

#	Article	IF	Citations
415	National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Annals of Internal Medicine, 2003, 139, 137.	2.0	3,780
416	National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines for Chronic Kidney Disease in Children and Adolescents: Evaluation, Classification, and Stratification. Pediatrics, 2003, 111, 1416-1421.	1.0	566
417	Traditional Cardiovascular Disease Risk Factors in Dialysis Patients Compared with the General Population: The CHOICE Study. Journal of the American Society of Nephrology: JASN, 2002, 13, 1918-1927.	3.0	531
418	Estimating the Prevalence of Low Glomerular Filtration Rate Requires Attention to the Creatinine Assay Calibration. Journal of the American Society of Nephrology: JASN, 2002, 13, 2811-2816.	3.0	107
419	The Timing of Specialist Evaluation in Chronic Kidney Disease and Mortality. Annals of Internal Medicine, 2002, 137, 479.	2.0	408
420	Nondiabetic Kidney Disease. New England Journal of Medicine, 2002, 347, 1505-1511.	13.9	121
421	Anemia as a risk factor for cardiovascular disease in the atherosclerosis risk in communities (aric) study. Journal of the American College of Cardiology, 2002, 40, 27-33.	1.2	435
422	Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis. New England Journal of Medicine, 2002, 347, 2010-2019.	13.9	1,664
423	Hyperhomocysteinemia in Renal Transplant Recipients. American Journal of Transplantation, 2002, 2, 308-313.	2.6	44
424	Comparison of causes of death using HEMO study and HCFA end-stage renal disease death notification classification systems. American Journal of Kidney Diseases, 2002, 39, 146-153.	2.1	96
425	Comorbidity and other factors associated with modality selection in incident dialysis patients: The CHOICE study. American Journal of Kidney Diseases, 2002, 39, 324-336.	2.1	139
426	Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. American Journal of Kidney Diseases, 2002, 39, 920-929.	2.1	667
427	Homocysteine, cysteine, and B vitamins as predictors of kidney disease progression. American Journal of Kidney Diseases, 2002, 40, 932-939.	2.1	36
428	Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. Kidney International, 2002, 62, 2208-2215.	2.6	74
429	Opinion: How Can the Cardiac Death Rate be Reduced in Dialysis Patients?. Seminars in Dialysis, 2002, 15, 18-20.	0.7	6
430	Plasma Total Homocysteine Levels among Patients Undergoing Nocturnal versus Standard Hemodialysis. Journal of the American Society of Nephrology: JASN, 2002, 13, 265-268.	3.0	68
431	Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. Journal of the American College of Cardiology, 2001, 38, 955-962.	1.2	638
432	Resistance Training To Counteract the Catabolism of a Low-Protein Diet in Patients with Chronic Renal Insufficiency. Annals of Internal Medicine, 2001, 135, 965.	2.0	204

#	Article	IF	Citations
433	U.S. NEPHROLOGISTS??? ATTITUDES TOWARDS RENAL TRANSPLANTATION: RESULTS FROM A NATIONAL SURVEY. Transplantation, 2001, 71, 281-288.	0.5	60
434	Prediction equations to estimate glomerular filtration rate: an update. Current Opinion in Nephrology and Hypertension, 2001, 10, 785-792.	1.0	249
435	Estimating the glomerular filtration rate. Postgraduate Medicine, 2001, 110, 55-62.	0.9	56
436	The national epidemic of chronic kidney disease. Postgraduate Medicine, 2001, 110, 23-29.	0.9	16
437	Comorbidity assessment using the Index of Coexistent Diseases in a multicenter clinical trial. Kidney International, 2001, 60, 1498-1510.	2.6	157
438	Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney International, 2001, 60, 1131-1140.	2.6	334
439	The Kidney and Homocysteine Metabolism. Journal of the American Society of Nephrology: JASN, 2001, 12, 2181-2189.	3.0	234
440	Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney International, 2000, 58, 353-362.	2.6	662
441	The role of systemic hypertension in the progression of nondiabetic renal disease. Kidney International, 2000, 57, S44-S48.	2.6	35
442	Comorbidity Assessment in Hemodialysis and Peritoneal Dialysis Using the Index of Coexistent Disease. Seminars in Dialysis, 2000, 13, 320-326.	0.7	95
443	Design and Statistical Issues of the Hemodialysis (HEMO) Study. Contemporary Clinical Trials, 2000, 21, 502-525.	2.0	128
444	Epidemiology, diagnosis, and management of cardiac disease in chronic renal disease. Journal of Thrombosis and Thrombolysis, 2000, 10, 169-180.	1.0	44
445	Cardiovascular disease and chronic renal disease: A new paradigm. American Journal of Kidney Diseases, 2000, 35, S117-S131.	2.1	482
446	US nephrologistsâ€™ recommendation of dialysis modality: Results of a national survey. American Journal of Kidney Diseases, 2000, 36, 1155-1165.	2.1	77
447	Late Initiation of Dialysis among Women and Ethnic Minorities in the United States. Journal of the American Society of Nephrology: JASN, 2000, 11, 2351-2357.	3.0	150
448	Validation of Comorbid Conditions on the End-Stage Renal Disease Medical Evidence Report. Journal of the American Society of Nephrology: JASN, 2000, 11, 520-529.	3.0	277
449	Placement of an internal jugular dialysis catheter into the superior intercostal vein. Nephrology Dialysis Transplantation, 1999, 14, 2028-2029.	0.4	16
450	Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. Kidney International, 1999, 56, 700-706.	2.6	60

#	Article	IF	Citations
451	Epidemiology of Cardiac Disease in Dialysis Patients. Seminars in Dialysis, 1999, 12, 69-76.	0.7	60
452	Level of renal function at the initiation of dialysis in the U.S. end-stage renal disease population. Kidney International, 1999, 56, 2227-2235.	2.6	102
453	A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation. Annals of Internal Medicine, 1999, 130, 461.	2.0	13,300
454	Remission of nephrotic syndrome in type 1 diabetes: Long-term follow-up of patients in the Captopril Study. American Journal of Kidney Diseases, 1999, 34, 308-314.	2.1	101
455	Dietary Protein Restriction and the Progression of Chronic Renal Disease. Journal of the American Society of Nephrology: JASN, 1999, 10, 2426-2439.	3.0	338
456	â€œUâ€•curve association of blood pressure and mortality in hemodialysis patients. Kidney International, 1998, 54, 561-569.	2.6	581
457	Effect of hepatitis C infection and renal transplantation on survival in end-stage renal disease11See Editorial by Goral and Helderman, p. 1420.. Kidney International, 1998, 53, 1374-1381.	2.6	282
458	Predictors of GBV-C infection among patients referred for renal transplantation. Kidney International, 1998, 53, 1769-1774.	2.6	5
459	Antilymphocyte Antibodies, Renal Transplantation, and Meta-Analysis. Annals of Internal Medicine, 1998, 128, 863.	2.0	5
460	Hepatitis C virus infection in dialysis and renal transplantation. Kidney International, 1997, 51, 981-999.	2.6	341
461	Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study. Kidney International, 1997, 52, 778-791.	2.6	192
462	GB HEPATITIS AGENT IN CADAVER ORGAN DONORS AND THEIR RECIPIENTS1,2. Transplantation, 1997, 63, 346-351.	0.5	15
463	LONG-TERM FOLLOW-UP OF HEPATITIS C VIRUS INFECTION AMONG ORGAN TRANSPLANT RECIPIENTS. Transplantation, 1997, 63, 849-853.	0.5	83
464	Achievement and Safety of a Low Blood Pressure Goal in Chronic Renal Disease. Hypertension, 1997, 29, 641-650.	1.3	186
465	Effects of Blood Pressure Control on Progressive Renal Disease in Blacks and Whites. Hypertension, 1997, 30, 428-435.	1.3	128
466	Effects of dietary protein restriction on the progression of advanced renal disease in the modification of diet in renal disease study. American Journal of Kidney Diseases, 1996, 27, 652-663.	2.1	300
467	Choices for Healthy Outcomes In Caring for End Stage Renal Disease. Seminars in Dialysis, 1996, 9, 9-11.	0.7	60
468	The Hemodialysis (HEMO) Study: Rationale for Selection of Interventions. Seminars in Dialysis, 1996, 9, 24-33.	0.7	90

#	Article	IF	Citations
469	Screening for acquired cystic kidney disease: A decision analytic perspective. Kidney International, 1995, 48, 207-219.	2.6	68
470	Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney International, 1995, 47, 236-240.	2.6	104
471	Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: A U.S. National Collaborative Study. Kidney International, 1994, 46, 886-892.	2.6	69
472	The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease. New England Journal of Medicine, 1994, 330, 877-884.	13.9	2,136
473	Assessing the Effectiveness of Therapy to Prevent the Progression of Renal Disease. American Journal of Kidney Diseases, 1993, 22, 207-214.	2.1	25
474	Prevalence of Hepatitis C Virus RNA in Organ Donors Positive for Hepatitis C Antibody and in the Recipients of Their Organs. New England Journal of Medicine, 1992, 327, 910-915.	13.9	257
475	Progression and Remission of Renal Disease in the Lupus Nephritis Collaborative Study. Annals of Internal Medicine, 1992, 116, 114-123.	2.0	120
476	Role of pathology indices in the management of severe lupus glomerulonephritis. Kidney International, 1992, 42, 743-748.	2.6	72
477	In vitro production of interleukin-1 receptor antagonist in chronic renal failure, CAPD and HD. Kidney International, 1992, 42, 1419-1424.	2.6	53
478	Transmission of Hepatitis C Virus by Organ Transplantation. New England Journal of Medicine, 1991, 325, 454-460.	13.9	388
479	WHICH RENAL TRANSPLANT PATIENTS SHOULD RECEIVE CYTOMEGALOVIRUS IMMUNE GLOBULIN?. Transplantation, 1991, 52, 259-265.	0.5	39
480	Donor specific transfusions or cyclosporine for related-donor kidney transplantation?. Kidney International, 1989, 36, 485-496.	2.6	6
481	LIFE-THREATENING THROMBOCYTOPENIA COMPLICATING ANTITHYMOCYTE GLOBULIN THERAPY FOR ACUTE KIDNEY TRANSPLANT REJECTION. Transplantation, 1988, 45, 647-648.	0.5	12
482	Use of Cytomegalovirus Immune Globulin to Prevent Cytomegalovirus Disease in Renal-Transplant Recipients. New England Journal of Medicine, 1987, 317, 1049-1054.	13.9	571
483	Idiopathic Nephrotic Syndrome. Annals of Internal Medicine, 1987, 107, 697.	2.0	37
484	Use of Magnesium Hydroxide and Low Magnesium Dialysate Does Not Permit Reduction of Aluminum Hydroxide During Continuous Ambulatory Peritoneal Dialysis. American Journal of Kidney Diseases, 1986, 8, 192-195.	2.1	7
485	Kidney Transplantation from Unrelated Living Donors. New England Journal of Medicine, 1986, 314, 914-916.	13.9	101
486	Kidney Failure or Cancer. Medical Decision Making, 1984, 4, 83-107.	1.2	18

#	Article	IF	Citations
487	Immune Complex Glomerulonephritis in Hydralazine-Induced SLE. American Journal of Kidney Diseases, 1984, 3, 270-274.	2.1	29
488	Metabolic alkalosis due to absorption of â€œnonabsorbableâ€•antacids. American Journal of Medicine, 1983, 74, 155-158.	0.6	34
489	Occult Intracranial Aneurysms in Polycystic Kidney Disease. New England Journal of Medicine, 1983, 308, 986-994.	13.9	131
490	Idiopathic Nephrotic Syndrome in a 53-Year-Old Woman. Medical Decision Making, 1982, 2, 497-519.	1.2	14